Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: A Proposed Classification and Treatment Strategies

Author(s): Namit Kant Singh*, Neemu Hage, Balaji Ramamourthy and Krishna Medha Kappagantu

Volume 22, Issue 8, 2022

Published on: 17 August, 2022

Article ID: e080422203295 Pages: 7

DOI: 10.2174/1871526522666220408110135

Abstract

Objectives: Mucormycosis is a rare fungal disease, which was known to affect only immunocompromised hosts, but during the COVID-19 pandemic, a surge in the cases of rhino- orbital-cerebral mucormycosis have been reported; however, the cause is still unknown. As the disease was a rare entity, there was no classification considering the spread and proper management at various stages.

Methods: Extensive literature search with the terms “mucormycosis,” “invasive fungal sinusitis,” “COVID-19 associated mucormycosis,” and “mucormycosis in COVID-19” was conducted on Pubmed, Scopus, and Embase database, taking into consideration case histories, revealing the site of involvement and treatment based on the disease's extent.

Results: Relevant articles were analyzed, and it was found that there is no specific classification of the disease entity and no proper surgical and medical management guidelines to date,

Conclusion: This review is an attempt to elaborate on the pathophysiology of mucormycosis and its spread and propose a classification that will help determine policies for the control and prevention of complications, morbidity, and mortality.

Keywords: Mucormycosis, mucorales, mucoricin, angio-invasion, GRP 78, COVID-19.

Graphical Abstract

[1]
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 1): S23-34.
[http://dx.doi.org/10.1093/cid/cir866] [PMID: 22247442]
[2]
Hassan MIA, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol 2019; 57 (Suppl. 2): S245-56.
[http://dx.doi.org/10.1093/mmy/myz011] [PMID: 30816980]
[3]
Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, Edwards JEJ Jr. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005; 73(2): 999-1005.
[http://dx.doi.org/10.1128/IAI.73.2.999-1005.2005] [PMID: 15664943]
[4]
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13(2): 236-301.
[http://dx.doi.org/10.1128/CMR.13.2.236] [PMID: 10756000]
[5]
Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 2013; 8(9): 1163-75.
[http://dx.doi.org/10.2217/fmb.13.78] [PMID: 24020743]
[6]
Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98(4): 492-504.
[http://dx.doi.org/10.3324/haematol.2012.065110] [PMID: 22983580]
[7]
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634-53.
[http://dx.doi.org/10.1086/432579] [PMID: 16080086]
[8]
Caruso P, Longo M, Esposito K, Maiorino MI. Type 1 diabetes triggered by COVID-19 pandemic: A potential outbreak? Diabetes Res Clin Pract 2020; 164: 108219.
[http://dx.doi.org/10.1016/j.diabres.2020.108219] [PMID: 32442555]
[9]
Quan C, Spellberg B. Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc 2010; 7(3): 210-5.
[http://dx.doi.org/10.1513/pats.200906-033AL] [PMID: 20463250]
[10]
Foss NT, Foss-Freitas MC, Ferreira MAN, Cardili RN, Barbosa CMC, Foss MC. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab 2007; 33(6): 439-43.
[http://dx.doi.org/10.1016/j.diabet.2007.10.001] [PMID: 17997340]
[11]
Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007; 40(8): 1037-44.
[http://dx.doi.org/10.1590/S0100-879X2006005000143] [PMID: 17665039]
[12]
Chander J, Kaur M, Singla N, et al. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi (Basel) 2018; 4(2): E46.
[http://dx.doi.org/10.3390/jof4020046] [PMID: 29642408]
[13]
Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2(1): a006429.
[http://dx.doi.org/10.1101/cshperspect.a006429] [PMID: 22315715]
[14]
Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120(6): 1914-24.
[http://dx.doi.org/10.1172/JCI42164] [PMID: 20484814]
[15]
Shumilov E, Bacher U, Perske C, et al. In situ validation of the endothelial cell receptor GRP78 in a case of rhinocerebral mucormycosis. Antimicrob Agents Chemother 2018; 62(5): e00172-18.
[http://dx.doi.org/10.1128/AAC.00172-18] [PMID: 29483124]
[16]
Anand VK, Alemar G, Griswold JAJ Jr. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope 1992; 102(6): 656-62.
[http://dx.doi.org/10.1288/00005537-199206000-00011] [PMID: 1602914]
[17]
Soliman SSM, Baldin C, Gu Y, et al. Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nat Microbiol 2021; 6(3): 313-26.
[http://dx.doi.org/10.1038/s41564-020-00837-0] [PMID: 33462434]
[18]
Mekki SO, Hassan AA, Falemban A, et al. Pulmonary mucormycosis: a case report of a rare infection with potential diagnostic problems. Case Reports Pathol 2020; 2020: 5845394.
[http://dx.doi.org/10.1155/2020/5845394]
[19]
Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 2005; 262(11): 932-8.
[http://dx.doi.org/10.1007/s00405-005-0919-0] [PMID: 15891927]
[20]
Higo T, Kobayashi T, Yamazaki S, et al. Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia. Int J Clin Exp Pathol 2015; 8(10): 13639-42.
[PMID: 26722589]
[21]
Sipsas Nv, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi (Basel) 2018; 4(3): 90.
[http://dx.doi.org/10.3390/jof4030090]
[22]
Szalai G, Fellegi V, Szabó Z, Vitéz LC. Mucormycosis mimicks sinusitis in a diabetic adult. Ann N Y Acad Sci 2006; 1084: 520-30.
[http://dx.doi.org/10.1196/annals.1372.010]
[23]
Chermetz M, Gobbo M, Rupel K, et al. Combined Orofacial aspergillosis and mucormycosis: fatal complication of a recurrent paediatric glioma-case report and review of literature. Mycopathologia 2016; 181(9-10): 723-33.
[http://dx.doi.org/10.1007/s11046-016-0021-8] [PMID: 27350324]
[24]
Bhandari J, Thada PK, Nagalli S. Rhinocerebral Mucormycosis. Tressure Island: Star Pearls Publishing 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/32644714/ Accessed December 1, 2021
[25]
Adegbola SOA, Banerjee A, Mulcahy MP. Rhinocerebral mucormycosis. Br J Hosp Med (Lond) 2009; 70(5): 298-9.
[http://dx.doi.org/10.12968/hmed.2009.70.5.42238] [PMID: 19451879]
[26]
Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24(2): 247-80.
[http://dx.doi.org/10.1128/CMR.00053-10] [PMID: 21482725]
[27]
Kung VL, Chernock RD, Burnham CAD. Diagnostic accuracy of fungal identification in histopathology and cytopathology specimens. Eur J Clin Microbiol Infect Dis 2018; 37(1): 157-65.
[http://dx.doi.org/10.1007/s10096-017-3116-3] [PMID: 29027030]
[28]
Dhaliwal HS, Singh A, Sinha SK, et al. Diagnosed only if considered: isolated renal mucormycosis. Lancet 2015; 385(9984): 2322.
[http://dx.doi.org/10.1016/S0140-6736(15)60730-9] [PMID: 26088500]
[29]
Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125(3): 375-8.
[http://dx.doi.org/10.5858/2001-125-0375-HFOZ] [PMID: 11231486]
[30]
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19(12): e405-21.
[http://dx.doi.org/10.1016/S1473-3099(19)30312-3] [PMID: 31699664]
[31]
Han Q, Escott EJ. The black turbinate sign, a potential diagnostic pitfall: evaluation of the normal enhancement patterns of the nasal turbinates. AJNR Am J Neuroradiol 2019; 40(5): 855-61.
[http://dx.doi.org/10.3174/ajnr.A6037] [PMID: 31000527]
[32]
Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021; 69(6): 1361-5.
[http://dx.doi.org/10.4103/ijo.IJO_1165_21] [PMID: 34011699]
[33]
Binder U, Maurer E, Lass-Flörl C. Mucormycosis--from the pathogens to the disease. Clin Microbiol Infect 2014; 20 (Suppl. 6): 60-6.
[http://dx.doi.org/10.1111/1469-0691.12566] [PMID: 24476149]
[34]
Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102(3): 433-44.
[http://dx.doi.org/10.3324/haematol.2016.152900] [PMID: 28011902]
[35]
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018; 56 (Suppl. 1): 93-101.
[http://dx.doi.org/10.1093/mmy/myx101] [PMID: 29538730]

Rights & Permissions Print Cite
Article Metrics
20
2
© 2024 Bentham Science Publishers | Privacy Policy